Therapy of microcirculatory disorders in severe acute pancreatitis: what mediators should we block?

Intensive Care Med. 2002 Feb;28(2):139-46. doi: 10.1007/s00134-001-1194-1. Epub 2002 Jan 17.

Abstract

Objective: To compare the effect of different vasoactive mediator antagonists in the same model of severe acute pancreatitis (AP) and to evaluate whether combinations of the agents exhibit synergistic effects.

Design: Prospective experimental study.

Setting: Microcirculation and pancreas research laboratory at an university hospital.

Participants: Hundred eighty anesthetized male Sprague-Dawley rats.

Interventions: Six hours after inducing AP by intra-ductal bile salt infusion and i.v. cerulein in 168 rats, these were randomized for therapy with (1) saline, (2) endothelin receptor antagonist (ET-RA), (3) platelet activating factor receptor antagonist (PAF-RA), (4) intercellular adhesion molecule-1 antibody (ICAM-1-AB) or different combinations (5-7). After 24 h the animals underwent a second laparotomy for intra-vital microscopic determination of pancreatic and colonic capillary permeability, blood flow and leukocyte-endothelial interaction.

Results: AP induction decreased capillary blood flow and increased permeability and leukocyte rolling. ET-RA, PAF-RA and ICAM-1-AB decreased capillary permeability, increased blood flow and reduced leukocyte rolling. ET-RA was most effective in decreasing capillary permeability in both organs as well as in increasing pancreatic capillary blood flow. Combining vasoactive mediator blockers did not further improve target parameters.

Conclusions: This study supports previous observations that ET-RA, PAF-RA and ICAM-1-AB improve microcirculation in AP and that ET-RA is more effective than PAF-RA or ICAM-1-AB, especially in counteracting capillary leakage. Although this may suggest that they act through different mechanisms, antagonist combinations failed to improve microcirculation further. We conclude that ET-RA is the most promising candidate for a clinical trial to reduce capillary leakage in patients with AP.

MeSH terms

  • Acute Disease
  • Animals
  • Antibodies / administration & dosage
  • Bile Acids and Salts / administration & dosage
  • Capillary Leak Syndrome / drug therapy
  • Ceruletide / administration & dosage
  • Endothelin Receptor Antagonists*
  • Intercellular Adhesion Molecule-1 / immunology*
  • Male
  • Microcirculation*
  • Pancreatitis / complications
  • Pancreatitis / physiopathology*
  • Platelet Membrane Glycoproteins / antagonists & inhibitors*
  • Prospective Studies
  • Rats
  • Rats, Sprague-Dawley
  • Receptors, Cell Surface*
  • Receptors, G-Protein-Coupled*
  • Vascular Diseases / complications
  • Vascular Diseases / drug therapy*
  • Vascular Diseases / physiopathology

Substances

  • Antibodies
  • Bile Acids and Salts
  • Endothelin Receptor Antagonists
  • Platelet Membrane Glycoproteins
  • Receptors, Cell Surface
  • Receptors, G-Protein-Coupled
  • platelet activating factor receptor
  • Intercellular Adhesion Molecule-1
  • Ceruletide